Achieved 22% total revenue growth in Q4 2025, driven by a 31% increase in clinical revenue as the core business re-accelerated toward historical levels.
Processed nearly 1 petabyte of genomic data in 2025, doubling volume from two years ago due to a market shift toward large comprehensive panels and multi-omic analysis.
Expanded adjusted gross margin by 140 basis points to 74.2% through a major architectural modernization that increased compute capacity tenfold and reduced whole genome analysis time to under 6 hours.
Secured two of the largest integrated health systems in the US, representing a combined potential of 60,000 annual genomic tests and 1 million oncology/rare disease patients.
Maintained high platform stickiness with annualized revenue churn below 1% and a Net Promoter Score of 67, validating the decentralized AI deployment model.
Announced a leadership transition with Ross Muken to become CEO in July 2026, while founder Jurgi Camblong moves to Executive Chairman to focus on technical innovation.
Leveraged a diverse data stream from 75 countries to launch ‘Digital Twins’ for lung cancer, enabling AI-driven virtual simulations for therapy selection.
Projecting 2026 revenue between $92 million and $94 million, with growth heavily back-half weighted as record 2025 bookings transition to routine usage.
Management anticipates a net positive biopharma contribution in 2026 as their story begins to resonate with senior members of top 20 pharmaceutical companies, though they are not yet forecasting a dramatic acceleration or ‘hockey stick’ growth for that year.
Targeting adjusted EBITDA breakeven by the end of 2026 and positive adjusted EBITDA in the second half of 2027 by dropping 60% of incremental revenue to the bottom line.
Assuming continued ASP expansion as customers migrate to higher-value products like MSK-ACCESS and Enhanced Exomes, despite lower-ASP volume growth in emerging markets.
Planning to hold operating expenses flat in local currency by flattening organizational structures and optimizing discretionary spending.
Reported significant adverse foreign exchange impacts due to a 14% appreciation of the Swiss franc, which inflated payroll and rent expenses in US dollar terms.
Incurred $1.8 million in legal expenses related to patent litigation with Guardant Health; however, the Unified Patent Court recently rejected Guardant’s request for provisional measures.
Strengthened liquidity by raising $15.5 million through an ATM facility and expanding a credit facility with Perceptive Advisors by $25 million.
Identified a record low net dollar retention of 115%, up from 104% in the prior year, driven by successful cross-selling of additional clinical applications.
